Osteoporosis is an adulthood disease that is usually marked by low bone mass and poor structure. The abilities of existing agents like estrogen, calcitonin, calcium, and bisphosphonates limit current treatment planning strategies. While they decrease fracture rate, they inhibit bone remodeling and only maintain or modestly improve existing bone mass and structure. Persons with osteoporotic fractures need approaches that induce marked skeletal improvement. Flouride offers hope, but more promising regulatory agents that stimulate formation to substantially improve bone mass and structure have enjoyed success in preclinical trials and are now in early clinical testing.
|Original language||English (US)|
|Number of pages||24|
|Journal||Rheumatic Disease Clinics of North America|
|State||Published - 1994|
ASJC Scopus subject areas